Lactobacillus crispatus VPro 31 and Safety in Terms of Adverse Events

• Phase 2a Study Assessing Colonization Efficiency, Safety, and Acceptability of Lactobacillus crispatus CTV-05 in Women With Bacterial Vaginosis

  • 2010-12
  • RCT · n = 24
  • Sexually Transmitted Diseases 37(12)
  • • A. Hemmerling
    • William G. Harrison
    • A. Schroeder
    • Je-Bok Park
    • A. Korn
    • S. Shiboski
    • A. Foster-Rosales
    • C. Cohen

  • PubMed: 20644497
  • DOI: 10.1097/OLQ.0b013e3181e50026

  11 Insights on

  • Safety in Terms of Adverse Events

  • High evidence
  • Highly Cited

  Of the 120 adverse events (AEs) that occurred, 108 (90%) and 12 (10%) were of mild and moderate severity, respectively. AEs were evenly distributed between the LACTIN-V and placebo group.

  Effect

  Neutral

  Effect size

  Small